No profile data available.
Silexion Therapeutics Corp (SLXN) is a healthcare company in the additional cancer treatment drugs industry, based in Jerusalem, Israel, with about 13 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$11.91 million. Its market capitalization was $3.11 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Silexion Therapeutics reported $0 in revenue for fiscal year 2025.
$3.11 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Processa Pharmaceuticals, Inc. (PCSA), Calidi Biotherapeutics, Inc. (CLDI), Indaptus Therapeutics, Inc. (INDP), Mustang Bio, Inc. (MBIO).